Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 9/20 | 0.73 |
| ▸ | HTR1A | P08908 | 4/20 | 0.73 |
| ▸ | HTR2A | P28223 | 2/20 | 0.73 |
| ▸ | HTR7 | P34969 | 3/20 | 0.68 |
| ▸ | HTR2B | P41595 | 1/20 | 0.68 |
| ▸ | HTR6 | P50406 | 1/20 | 0.68 |
| ▸ | DRD4 | P21917 | 3/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | DRD3 | P35462 | 2/20 | 0.55 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8032044 | 0.90 | DRD2 (0.74) | DRD2HTR1AHTR2AHTR7HTR2B | |
| SCHEMBL10428494 | 0.88 | DRD2 (0.64) | DRD2HTR1AHTR2AHTR7HTR2B | |
| SCHEMBL10428489 | 0.87 | DRD2 (0.69) | DRD2HTR1AHTR2AHTR7HTR2B | |
| SCHEMBL31038574 | 0.85 | DRD2 (1.00) | DRD2HTR1AHTR2AHTR7HTR2B | |
| SCHEMBL3408535 | 0.85 | DRD2 (1.00) | DRD2HTR1AHTR2AHTR7HTR2B | |
| Hydrochloric Acid SCHEMBL31038578 | 0.84 | DRD2 (0.98) | DRD2HTR1AHTR2AHTR7HTR2B | |
| Hydrochloric Acid SCHEMBL3404095 | 0.84 | DRD2 (0.98) | DRD2HTR1AHTR2AHTR7HTR2B | |
| SCHEMBL14974957 | 0.83 | DRD2 (0.86) | DRD2HTR1AHTR2AHTR7HTR2B | |
| SCHEMBL8160207 | 0.83 | DRD2 (0.80) | DRD2HTR1AHTR2AHTR7HTR2B | |
| Brilaroxazine SCHEMBL3404085 | 0.81 | DRD2 (1.00) | DRD2HTR1AHTR2AHTR7HTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230061592-A1 | METHODS FOR TREATING PULMONARY FIBROSIS | REVIVA PHARMACEUTICALS, INC. | 2023-03-02 | — | — | US | disclosed |
| US-20210128570-A1 | METHODS FOR TREATING PULMONARY FIBROSIS | REVIVA PHARMACEUTICALS INC (US) | 2021-05-06 | — | — | US | disclosed |
| US-10441590-B2 | Methods for treating pulmonary hypertension | REVIVA PHARMACEUTICALS, INC. (US) | 2019-10-15 | — | — | US | disclosed |
| US-20190142838-A1 | METHODS FOR TREATING PARKINSON'S DISEASE | REVIVA PHARMACEUTICALS INC (US) | 2019-05-16 | — | — | US | disclosed |
| US-20180125851-A1 | METHODS FOR TREATING PULMONARY HYPERTENSION | REVIVA PHARMACEUTICALS, INC. | 2018-05-10 | — | — | US | disclosed |
| US-20180071298-A1 | METHODS FOR TREATING ALZHEIMER'S DISEASE | REVIVA PHARMACEUTICALS, INC. | 2018-03-15 | — | — | US | disclosed |
| US-20180071299-A1 | METHODS FOR TREATING PSYCHOSIS ASSOCIATED WITH PARKINSON'S DISEASE | REVIVA PHARMACEUTICALS, INC. | 2018-03-15 | — | — | US | disclosed |
| US-9907803-B2 | Methods for treating attention deficit hyperactivity disorder | REVIVA PHARMACEUTICALS, INC. (US) | 2018-03-06 | — | — | US | disclosed |
| US-20170035772-A1 | METHODS FOR TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER | REVIVA PHARMACEUTICALS INC (US) | 2017-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210128570-A1 | METHODS FOR TREATING PULMONARY FIBROSIS | MMP1, CCL11, PAH | DRD2 4417/4885HTR1A 1544/4885HTR2A 1984/4885 |
| US-20180071298-A1 | METHODS FOR TREATING ALZHEIMER'S DISEASE | PSEN1, PSEN2, APP | DRD2 380/4885HTR1A 39/4885HTR2A 18/4885 |
| US-20180125851-A1 | METHODS FOR TREATING PULMONARY HYPERTENSION | CYP11B2, PAH, CYP11B1 | DRD2 3542/4885HTR1A 453/4885HTR2A 541/4885 |
| US-20190142838-A1 | METHODS FOR TREATING PARKINSON'S DISEASE | PARK7, COMT, SNCA | DRD2 302/4885HTR1A 116/4885HTR2A 35/4885 |
| US-20180071299-A1 | METHODS FOR TREATING PSYCHOSIS ASSOCIATED WITH PARKINSON'S DISEASE | PARK7, SNCA, COMT | DRD2 87/4885HTR1A 27/4885HTR2A 33/4885 |
| US-20230061592-A1 | METHODS FOR TREATING PULMONARY FIBROSIS | MMP1, CCL11, PAH | DRD2 4417/4885HTR1A 1544/4885HTR2A 1984/4885 |
| US-20170035772-A1 | METHODS FOR TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER | HTR2C, SLC6A2, HTR5A | DRD2 36/4885HTR1A 12/4885HTR2A 6/4885 |
| US-10441590-B2 | Methods for treating pulmonary hypertension | CYP11B2, PAH, CYP11B1 | DRD2 3542/4885HTR1A 453/4885HTR2A 541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.